Antibody Drug Conjugates in Glioblastoma - Is There a Future for Them?
antibody drug conjugates (ADC)
biomarkers
blood brain barrier
glioblastoma
glioma
molecular imaging
tumour microenvironment
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
01
06
2021
accepted:
15
11
2021
entrez:
20
12
2021
pubmed:
21
12
2021
medline:
21
12
2021
Statut:
epublish
Résumé
Glioblastoma (GBM) is an aggressive and fatal malignancy that despite decades of trials has limited therapeutic options. Antibody drug conjugates (ADCs) are composed of a monoclonal antibody which specifically recognizes a cellular surface antigen linked to a cytotoxic payload. ADCs have demonstrated superior efficacy and/or reduced toxicity in a range of haematological and solid tumors resulting in nine ADCs receiving regulatory approval. ADCs have also been explored in patients with brain tumours but with limited success to date. While earlier generations ADCs in glioma patients have had limited success and high toxicity, newer and improved ADCs characterised by low immunogenicity and more effective payloads have shown promise in a range of tumour types. These newer ADCs have also been tested in glioma patients, however, with mixed results. Factors affecting the effectiveness of ADCs to target the CNS include the blood brain barrier which acts as a physical and biochemical barrier, the pro-cancerogenic and immunosuppressive tumor microenvironment and tumour characteristics like tumour volume and antigen expression. In this paper we review the data regarding the ongoing the development of ADCs in glioma patients as well as potential strategies to overcome these barriers to maximise their therapeutic potential.
Identifiants
pubmed: 34926242
doi: 10.3389/fonc.2021.718590
pmc: PMC8678283
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
718590Informations de copyright
Copyright © 2021 Parakh, Nicolazzo, Scott and Gan.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Clin Oncol. 2018 May 10;36(14):1419-1427
pubmed: 29432077
Molecules. 2020 Oct 16;25(20):
pubmed: 33081383
N Engl J Med. 2020 Feb 13;382(7):610-621
pubmed: 31825192
Cancer Res. 2006 Nov 15;66(22):10815-23
pubmed: 17090523
J Neurooncol. 2003 Oct;65(1):3-13
pubmed: 14649881
Cancer Res. 2000 Aug 15;60(16):4324-7
pubmed: 10969769
Neuro Oncol. 2020 May 15;22(5):684-693
pubmed: 31747009
Neurobiol Dis. 2010 Jan;37(1):13-25
pubmed: 19664713
JAMA Oncol. 2017 Aug 01;3(8):1094-1101
pubmed: 28426845
Neuro Oncol. 2021 Oct 1;23(10):1656-1667
pubmed: 33659980
Cancer Cell. 2015 Jan 12;27(1):15-26
pubmed: 25584892
Antibodies (Basel). 2018 Feb 07;7(1):
pubmed: 31544862
N Engl J Med. 2016 Dec 29;375(26):2561-9
pubmed: 28029927
Cancer Discov. 2020 May;10(5):688-701
pubmed: 32213540
Mol Cancer Ther. 2015 Apr;14(4):952-63
pubmed: 25646013
Natl Sci Rev. 2020 Aug;7(8):1306-1318
pubmed: 34692159
Adv Drug Deliv Rev. 1999 Apr 5;36(2-3):179-194
pubmed: 10837715
Nat Biomed Eng. 2019 Apr;3(4):264-280
pubmed: 30952988
Cancers (Basel). 2018 Dec 17;10(12):
pubmed: 30562956
J Clin Neurosci. 2015 Dec;22(12):1889-94
pubmed: 26279503
Mol Cancer Res. 2005 Oct;3(10):541-51
pubmed: 16254188
Clin Adv Hematol Oncol. 2009 Nov;7(11):753-60, 768
pubmed: 20075834
Drug Deliv. 2018 Nov;25(1):1634-1641
pubmed: 30176744
Sci Transl Med. 2015 Aug 26;7(302):302ra136
pubmed: 26311731
Cancer Res. 2018 Jul 15;78(14):4059-4072
pubmed: 29764866
Genes (Basel). 2021 Mar 20;12(3):
pubmed: 33804731
Invest New Drugs. 2015 Jun;33(3):671-8
pubmed: 25895099
Adv Exp Med Biol. 2020;1296:1-9
pubmed: 34185283
Nat Genet. 2016 Jul;48(7):768-76
pubmed: 27270107
Cancers (Basel). 2020 Oct 09;12(10):
pubmed: 33050158
Expert Opin Ther Targets. 2019 Dec;23(12):1005-1014
pubmed: 31825703
Sci Rep. 2016 Mar 16;6:23262
pubmed: 26979925
J Neurooncol. 2015 Apr;122(2):367-82
pubmed: 25630625
FEBS J. 2013 Nov;280(21):5350-70
pubmed: 23777544
Blood. 2017 Dec 21;130(25):2709-2717
pubmed: 28974506
Cancer Sci. 2016 Jul;107(7):1039-46
pubmed: 27166974
N Engl J Med. 2018 Jan 25;378(4):331-344
pubmed: 29224502
Clin Cancer Res. 2016 Oct 15;22(20):5097-5108
pubmed: 27026201
Angew Chem Int Ed Engl. 2017 Jan 9;56(2):462-488
pubmed: 27862776
Neuro Oncol. 2021 Dec 1;23(12):2042-2053
pubmed: 34050676
Regul Toxicol Pharmacol. 2019 Oct;107:104429
pubmed: 31325532
Sci Transl Med. 2015 Nov 25;7(315):315ra188
pubmed: 26606967
Nat Med. 2019 Mar;25(3):470-476
pubmed: 30742120
Neuro Oncol. 2010 Aug;12(8):871-81
pubmed: 20511192
Cancer Cell. 2015 Sep 14;28(3):318-28
pubmed: 26373279
Mol Cancer Ther. 2018 Jan;17(1):243-253
pubmed: 29054985
Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4071-6
pubmed: 17360479
Lancet. 2015 May 9;385(9980):1853-62
pubmed: 25796459
Nat Rev Cancer. 2004 Oct;4(10):806-13
pubmed: 15510161
Pharm Res. 2018 Jul 12;35(9):177
pubmed: 30003344
PLoS One. 2015 Jun 17;10(6):e0130692
pubmed: 26083390
Nature. 2019 Dec;576(7785):112-120
pubmed: 31748746
Acta Pharm Sin B. 2021 Dec;11(12):3889-3907
pubmed: 35024314
Sci Rep. 2020 Jun 18;10(1):9898
pubmed: 32555306
Cancer Cell. 2013 Feb 11;23(2):238-48
pubmed: 23410976
Nat Med. 2019 Mar;25(3):477-486
pubmed: 30742122
Mol Cancer Ther. 2012 Feb;11(2):308-16
pubmed: 22203732
Neuro Oncol. 2016 Aug;18(8):1037-9
pubmed: 27236194
Cancer Res. 2017 Sep 1;77(17):4639-4651
pubmed: 28687619
J Immunother Cancer. 2019 Mar 29;7(1):90
pubmed: 30922362
Neuro Oncol. 2019 Jul 11;21(7):923-933
pubmed: 30753611
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
N Engl J Med. 2016 Aug 25;375(8):740-53
pubmed: 27292104
Cancer Res. 2008 Nov 15;68(22):9367-74
pubmed: 19010911
J Clin Oncol. 2001 Jul 1;19(13):3244-54
pubmed: 11432892
Pharm Res. 2016 Dec;33(12):2930-2942
pubmed: 27528392
Org Biomol Chem. 2017 Jul 5;15(26):5635-5642
pubmed: 28649690
J Thorac Oncol. 2021 Sep;16(9):1547-1558
pubmed: 33607312
Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):4009-14
pubmed: 23412337
Curr Top Med Chem. 2009;9(2):130-47
pubmed: 19200001
Science. 2014 Jan 3;343(6166):72-6
pubmed: 24310612
J Immunother Cancer. 2019 May 29;7(1):142
pubmed: 31142380
Annu Rev Pharmacol Toxicol. 2017 Jan 6;57:61-79
pubmed: 28061688
Proc Natl Acad Sci U S A. 2019 May 14;116(20):10009-10018
pubmed: 31028138
Bioconjug Chem. 2013 Jul 17;24(7):1256-63
pubmed: 23808985
Leukemia. 2017 Aug;31(8):1779-1787
pubmed: 27922598
Pharmaceuticals (Basel). 2020 May 08;13(5):
pubmed: 32397088
Sci Rep. 2018 Jul 11;8(1):10479
pubmed: 29992976
J Neurooncol. 2003 Aug-Sep;64(1-2):125-37
pubmed: 12952293
J Biol Chem. 2007 Feb 2;282(5):2840-50
pubmed: 17092939
Lancet Oncol. 2017 Jun;18(6):743-754
pubmed: 28526538
Nat Commun. 2018 May 4;9(1):1484
pubmed: 29728559
Clin Cancer Res. 2019 Feb 15;25(4):1261-1271
pubmed: 30397180
Expert Opin Drug Deliv. 2016;13(3):401-19
pubmed: 26654403
Cancer Cell. 2017 Apr 10;31(4):501-515.e8
pubmed: 28399408
J Clin Oncol. 2017 Jan 20;35(3):343-351
pubmed: 27918718
Cancer Res. 2012 Jun 15;72(12):2924-30
pubmed: 22659454
Lancet. 2017 Aug 5;390(10094):555-566
pubmed: 28600132
J Neurooncol. 2016 Feb;126(3):447-54
pubmed: 26694547
Mol Cancer Ther. 2020 Oct;19(10):2117-2125
pubmed: 32847977
Adv Ther. 2017 May;34(5):1015-1035
pubmed: 28361465
Neuro Oncol. 2017 Jul 01;19(7):965-975
pubmed: 28039367
N Engl J Med. 2014 Feb 20;370(8):699-708
pubmed: 24552317
Mol Cancer Ther. 2015 Jun;14(6):1376-84
pubmed: 25840583
Clin Cancer Res. 2018 Dec 15;24(24):6570-6582
pubmed: 30131388
Invest New Drugs. 2013 Feb;31(1):77-84
pubmed: 22370972
Clin Cancer Res. 2013 Mar 15;19(6):1567-76
pubmed: 23349317
Expert Opin Drug Discov. 2018 Aug;13(8):685-690
pubmed: 29792354
Lancet. 2019 Jan 19;393(10168):229-240
pubmed: 30522922
Cancer Chemother Pharmacol. 2019 Aug;84(2):327-336
pubmed: 31154523
J Natl Cancer Inst. 2007 Oct 3;99(19):1441-54
pubmed: 17895480
J Clin Oncol. 2020 May 10;38(14):1505-1517
pubmed: 32150489
J Nucl Med. 2021 Jun 1;62(6):787-794
pubmed: 33509972
Breast Cancer (Dove Med Press). 2021 Feb 25;13:151-159
pubmed: 33658846
Cancer Manag Res. 2014 Aug 19;6:317-28
pubmed: 25170280
Pharmaceuticals (Basel). 2020 Sep 14;13(9):
pubmed: 32937862
Neuro Oncol. 2008 Apr;10(2):182-9
pubmed: 18287339
Am Soc Clin Oncol Educ Book. 2020 Mar;40:1-17
pubmed: 32315240
PLoS One. 2021 Feb 5;16(2):e0246646
pubmed: 33544755
Cancer Discov. 2014 Aug;4(8):956-71
pubmed: 24893890
Nat Rev Cancer. 2012 Mar 22;12(4):278-87
pubmed: 22437872
Clin Cancer Res. 2019 Sep 15;25(18):5441-5448
pubmed: 30979742
Lancet. 2012 Apr 21;379(9825):1508-16
pubmed: 22482940
Am Soc Clin Oncol Educ Book. 2013;:
pubmed: 23714470
Angew Chem Int Ed Engl. 2017 Jan 16;56(3):733-737
pubmed: 27966822
Acta Oncol. 1999;38(3):351-9
pubmed: 10380827
Mol Cancer Ther. 2015 Jul;14(7):1614-24
pubmed: 25931519
N Engl J Med. 2012 Nov 8;367(19):1783-91
pubmed: 23020162
Breast Cancer Res. 2014 May 23;16(3):R50
pubmed: 24887458
Cancer Res. 2016 May 1;76(9):2710-9
pubmed: 26921341
Lancet Oncol. 2017 Oct;18(10):1373-1385
pubmed: 28844499
NPJ Precis Oncol. 2021 Aug 5;5(1):74
pubmed: 34354225
Cancer Res. 2017 May 15;77(10):2686-2698
pubmed: 28283653
Cancers (Basel). 2020 Aug 05;12(8):
pubmed: 32764266
Neuro Oncol. 2008 Jun;10(3):320-9
pubmed: 18403491
Front Pharmacol. 2019 Apr 24;10:373
pubmed: 31068807
J Clin Oncol. 2010 Jun 1;28(16):2698-704
pubmed: 20421541
Neuro Oncol. 2018 Jan 22;20(2):184-191
pubmed: 29016900
Cancer Res. 2001 Jul 15;61(14):5355-61
pubmed: 11454674
N Engl J Med. 2021 Apr 22;384(16):1529-1541
pubmed: 33882206
Front Oncol. 2018 Oct 23;8:462
pubmed: 30406029
Annu Rev Med. 2013;64:15-29
pubmed: 23043493
Biochem Pharmacol. 2016 Feb 15;102:1-6
pubmed: 26686577
Nat Commun. 2018 Mar 6;9(1):785
pubmed: 29511178
J Med Chem. 2017 May 25;60(10):4510-4516
pubmed: 28471660
MAbs. 2016 May-Jun;8(4):659-71
pubmed: 27045800
Expert Opin Drug Saf. 2016 Jun;15(6):875-82
pubmed: 27139729
J Membr Biol. 2014 Apr;247(4):291-307
pubmed: 24573305
J Biol Chem. 2004 Jul 16;279(29):30375-84
pubmed: 15075331
Nat Rev Clin Oncol. 2017 Nov;14(11):695-707
pubmed: 28675164
Front Pharmacol. 2021 Jun 23;12:687926
pubmed: 34248637
Science. 2014 Jan 10;343(6167):189-193
pubmed: 24336570
Lancet Oncol. 2017 Jan;18(1):42-51
pubmed: 27932068
Mol Cancer Ther. 2016 Apr;15(4):661-9
pubmed: 26846818
J Neurosurg. 2010 Aug;113(2):192-8
pubmed: 20345222
N Engl J Med. 2014 Feb 20;370(8):709-22
pubmed: 24552318
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Clin Cancer Res. 2017 Nov 15;23(22):6846-6855
pubmed: 28855349